title: Stability of extemporaneously prepared glycopyrrolate oral suspensions.
abstract: OBJECTIVE
  The stability of extemporaneously prepared glycopyrrolate 0.5-mg/mL suspensions was evaluated.
  
  
  METHODS
  An oral suspension of glycopyrrolate 0.5 mg/mL was prepared by thoroughly grinding 30 1-mg tablets of glycopyrrolate in a glass mortar. Thirty milliliters of Ora-Plus and 30 mL of either Ora-Sweet or Ora-Sweet SF were mixed and added to the powder to make a final volume of 60 mL. Three identical samples of the formulation were prepared and placed in 2-oz amber plastic bottles with child-resistant caps and stored at room temperature (23-25 °C). A 1-mL sample was withdrawn from each of the three bottles with a micropipette immediately after preparation and 7, 15, 30, 60, and 90 days afterward. After further dilution to an expected concentration of 50 μg/mL with sample diluent, the samples were assayed in duplicate by stability-indicating high-performance liquid chromatography. The samples were visually examined for any color change and evaluated for pH on each day of analysis. Taste evaluations were performed at the beginning and end of the study. Stability was defined as the retention of at least 90% of the initial concentration.
  
  
  RESULTS
  At least 95% of the initial glycopyrrolate remained throughout the 90-day study period in both preparations. There were no detectable changes in color, odor, taste, and pH, and no visible microbial growth was observed in any sample.
  
  
  CONCLUSIONS
  Extemporaneously compounded suspensions of glycopyrrolate 0.5 mg/mL in a 1:1 mixture of Ora-Plus/Ora-Sweet or Ora-Plus/Ora-Sweet SF were stable for at least 90 days when stored in amber plastic bottles at room temperature.
authors.affiliation: Neonatal Intensive Care Unit, Department of Pharmacy, Akron Children’s Hospital, Akron, OH 44308, USA. mcober@chmca.org
authors.forename: Mary Petrea
authors.initials: MP
authors.lastname: Cober
authors.forename: Cary E
authors.initials: CE
authors.lastname: Johnson
authors.forename: David
authors.initials: D
authors.lastname: Sudekum
authors.forename: Kimberly
authors.initials: K
authors.lastname: Penprase
mesh_terms: D000284:Administration, Oral; D002851:Chromatography, High Pressure Liquid; D003116:Color; D004339:Drug Compounding; D004355:Drug Stability; D004356:Drug Storage; D006024:Glycopyrrolate / Q000008:administration & dosage / Q000737:chemistry*; D006863:Hydrogen-Ion Concentration; D018727:Muscarinic Antagonists / Q000008:administration & dosage / Q000737:chemistry*; D014677:Pharmaceutical Vehicles / Q000737:chemistry*; D013535:Suspensions; D013997:Time Factors
chemical_list: D018727:Muscarinic Antagonists; D014677:Pharmaceutical Vehicles; D013535:Suspensions; D006024:Glycopyrrolate